Compare Angi Inc (ANGI) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Angi Inc vs Danaher Corporation — how do they compare? Angi Inc trades at $4.42 (market cap $182.30M), while Danaher Corporation trades at $206.77 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 799.9× Angi Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Angi Inc pays none. Which is the better fit depends on your goals.
| ANGI | DHR | |
|---|---|---|
Market Cap | $182.30M | $145.83B |
Sector | Media | Health |
52-Week High | $18.46 | $242.05 |
52-Week Low | $4.49 | $161.91 |
Enterprise Value | $392.07M | $168.04B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANGI trades at $4.59, down 5.17% on the day, reflecting ongoing operational challenges. The stock is in a bearish technical trend, with revenue declining from $1.03B in 2025 to a projected $993M in 2026. Recent Q2 2026 earnings missed expectations significantly, with an EPS of -$5.7 versus an expected $0.1333, highlighting deep profitability issues. Negative net income margins and cash flow concerns persist, though valuation ratios like P/S of 0.19 and P/B of 0.27 appear low.
The outlook remains cautious due to accelerating user churn, revenue declines, and lack of clear catalysts. Analyst consensus is a Hold with a $7.00 price target, but risks include ongoing fraud investigations, competitive pressures, and negative cash flow trends. Upside potential exists if the company stabilizes its platform, but current fundamentals suggest continued headwinds for shareholder value.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
